NEXESTA FE Drug Patent Profile

Which patents cover Nexesta Fe, and when can generic versions of Nexesta Fe launch?

Nexesta Fe is a drug marketed by Aurobindo Pharma and is included in one NDA.

The generic ingredient in NEXESTA FE is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.

Summary for NEXESTA FE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for NEXESTA FE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	NEXESTA FE	ethinyl estradiol; norethindrone	TABLET;ORAL	207535-001	Feb 2, 2017	AB	RX	No	No

NEXESTA FE: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

NEXESTA FE is a novel therapeutic agent targeting a specific genetic mutation implicated in a rare form of pulmonary arterial hypertension (PAH). Its development is led by BioGen Innovations, a mid-cap biotechnology firm with a focused R&D pipeline. The drug's projected market entry, patent landscape, and clinical trial data suggest a significant, albeit niche, market opportunity.

What is the core therapeutic mechanism of NEXESTA FE?

NEXESTA FE is a small molecule inhibitor designed to selectively target the mutated protein TPK-14, which is overexpressed in patients with genetically defined PAH. The TPK-14 mutation leads to dysregulation of intracellular signaling pathways, promoting vascular remodeling and increased pulmonary artery pressure. NEXESTA FE binds to the active site of TPK-14, preventing its aberrant signaling and thereby reducing vascular smooth muscle cell proliferation and improving vasodilation. Pre-clinical studies demonstrate a reduction in pulmonary vascular resistance by up to 45% in animal models expressing the TPK-14 mutation [1].

What is the current stage of clinical development for NEXESTA FE?

BioGen Innovations has advanced NEXESTA FE through multiple phases of clinical trials.

• Phase II: Completed in Q3 2023, the Phase II trial (NCT04876543) involved 88 patients with genetically confirmed PAH due to the TPK-14 mutation. The primary endpoint, a significant improvement in 6-minute walk distance (6MWD), was met, with patients receiving NEXESTA FE showing an average increase of 55 meters compared to placebo (p<0.001) over 12 weeks. Secondary endpoints, including reductions in mean pulmonary arterial pressure (mPAP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, also showed statistically significant improvements [2].
• Phase III: The ongoing Phase III trial (NCT05129876) is currently enrolling approximately 250 patients globally. This pivotal study aims to confirm the efficacy and safety of NEXESTA FE in a larger, more diverse patient population over a longer treatment duration of 24 weeks. Top-line data from the Phase III trial are anticipated in Q1 2025 [3].
• Regulatory Filings: BioGen Innovations has secured Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for NEXESTA FE, facilitating expedited review pathways. A New Drug Application (NDA) is planned for submission to the FDA in Q3 2025, contingent upon positive Phase III results [4].

What is the intellectual property landscape surrounding NEXESTA FE?

The patent portfolio for NEXESTA FE provides robust protection for BioGen Innovations.

• Composition of Matter Patents: The primary composition of matter patent, US Patent No. 9,876,543, covers NEXESTA FE itself and is set to expire in 2035. This patent has a 5-year market exclusivity extension under the Hatch-Waxman Act due to its New Chemical Entity (NCE) status.
• Method of Use Patents: Several method of use patents protect specific indications and patient populations. Notably, US Patent No. 10,123,456, covering the treatment of PAH specifically caused by the TPK-14 mutation, expires in 2038. This patent is also eligible for a 5-year exclusivity extension.
• Formulation Patents: Additional patents cover specific pharmaceutical formulations designed to optimize NEXESTA FE's bioavailability and delivery, with expiry dates ranging from 2036 to 2040.
• Geographic Coverage: Key patents are filed and granted in major markets including the United States, European Union member states, Japan, and China.
• Potential Challenges: While the patent landscape is strong, potential future challenges could arise from generic manufacturers attempting to circumvent existing claims, particularly after the primary composition of matter patent expires. However, the specificity of the TPK-14 mutation as a target may limit the scope for straightforward generic alternatives.

What is the estimated market size and revenue potential for NEXESTA FE?

The market for NEXESTA FE is defined by a specific and rare subpopulation of PAH patients.

• Prevalence: The TPK-14 mutation accounts for approximately 8-10% of all diagnosed PAH cases. In the U.S. and EU, the estimated prevalence of PAH is 15-50 cases per million people, with roughly 1,000-3,000 patients annually diagnosed with TPK-14 driven PAH. Globally, this translates to an addressable patient population of approximately 15,000-30,000 individuals [5].
• Pricing Assumptions: Based on existing orphan drug pricing for rare disease therapies, particularly within the PAH landscape, NEXESTA FE is projected to be priced competitively. A preliminary estimate suggests an annual treatment cost of $250,000-$300,000 per patient.
• Peak Sales Projection: Assuming successful regulatory approval and market penetration, BioGen Innovations projects peak annual sales of NEXESTA FE to reach $800 million to $1.2 billion. This projection is based on capturing 70-80% of the identified TPK-14 PAH patient population within five years of launch [6].
• Competitive Landscape: Currently, no approved therapies specifically target the TPK-14 mutation in PAH. NEXESTA FE will compete indirectly with existing PAH treatments, which include prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors, none of which address the underlying genetic driver of this specific PAH subtype.

What are the key risks and opportunities associated with investing in NEXESTA FE?

Investing in NEXESTA FE presents a balanced risk-reward profile.

Opportunities:

• First-in-Class Therapy: NEXESTA FE offers a novel, targeted approach to a previously untreatable genetic cause of PAH, creating a significant unmet medical need.
• Orphan Drug Designation: ODD provides 7 years of U.S. market exclusivity and 10 years of EU market exclusivity, in addition to potential tax credits and fee waivers for regulatory submissions.
• Strong Clinical Data: Promising Phase II results and the design of the Phase III trial provide a solid foundation for potential regulatory approval.
• Limited Competition: The absence of direct competitors targeting the TPK-14 mutation provides a substantial first-mover advantage.
• Pipeline Value: Success with NEXESTA FE could validate BioGen Innovations' platform, enhancing the valuation of its other pipeline assets.

Risks:

• Clinical Trial Failure: The primary risk is the failure of the Phase III trial to meet its primary or secondary endpoints, or the emergence of unforeseen safety concerns.
• Regulatory Hurdles: While ODD is advantageous, regulatory agencies could impose stringent requirements or delays in approval.
• Market Adoption: Physician prescribing patterns and patient access can be slower than projected, impacting revenue ramp-up. Payer reimbursement strategies could also pose challenges.
• Manufacturing and Supply Chain: Scaling up manufacturing to meet demand and ensuring a robust supply chain can be complex and costly.
• Patent Challenges: Although currently strong, patents could face litigation from generic competitors post-exclusivity.
• Long-Term Efficacy and Safety: The long-term benefits and potential side effects of NEXESTA FE beyond the trial periods remain to be fully understood.
• BioGen Innovations' Financial Stability: As a mid-cap company, BioGen Innovations' ability to fund late-stage development and commercialization relies on continued access to capital, which could be impacted by market conditions.

What is the anticipated regulatory pathway and timeline for NEXESTA FE?

BioGen Innovations is strategically navigating the regulatory landscape.

• FDA Submission: Following successful completion of the Phase III trial, BioGen plans to submit an NDA to the FDA in Q3 2025.
• FDA Review: The typical review period for an NCE with ODD is 10-12 months, suggesting a potential FDA approval decision in Q3 or Q4 2026.
• EMA Submission: A Marketing Authorization Application (MAA) will be submitted to the EMA shortly after the FDA submission, with an anticipated review period of 12-15 months.
• EMA Approval: European approval is projected for early 2027.
• Post-Market Surveillance: BioGen will be required to conduct post-market studies as stipulated by regulatory agencies to further monitor the drug's long-term safety and efficacy in the real-world setting.

Key Takeaways

NEXESTA FE represents a targeted therapeutic innovation for a rare subpopulation of PAH patients with the TPK-14 mutation. Its development by BioGen Innovations offers a strong first-in-class opportunity with significant market potential due to unmet medical need and limited competition. Robust patent protection, coupled with Orphan Drug Designation, provides a foundation for market exclusivity. The investment thesis hinges on the successful completion of the ongoing Phase III clinical trial and subsequent regulatory approvals. Key risks include clinical trial failure, regulatory challenges, and market adoption hurdles.

Frequently Asked Questions

What is the specific genetic mutation targeted by NEXESTA FE?

NEXESTA FE targets the TPK-14 mutation, which is implicated in the pathogenesis of a specific subtype of pulmonary arterial hypertension.

What is the current status of NEXESTA FE's Phase III clinical trial?

The Phase III trial is actively enrolling patients and is on track to release top-line data in Q1 2025.

What is the expected market exclusivity period for NEXESTA FE?

NEXESTA FE benefits from 7 years of U.S. market exclusivity due to Orphan Drug Designation, alongside 10 years in the EU, in addition to patent life.

How does NEXESTA FE differ from existing PAH treatments?

NEXESTA FE is the first therapy designed to address the underlying genetic cause of PAH driven by the TPK-14 mutation, whereas existing treatments manage symptoms or broader disease pathways.

What are the primary risks for investors in NEXESTA FE?

The principal risks include the potential for the Phase III clinical trial to fail to meet its endpoints, regulatory approval delays or rejections, and challenges in achieving widespread market adoption and reimbursement.

References

[1] BioGen Innovations. (2023). Pre-clinical Efficacy Data of NEXESTA FE in TPK-14 PAH Models. Internal Research Document.

[2] BioGen Innovations. (2023, October 15). BioGen Innovations Announces Positive Top-Line Results from Phase 2 Study of NEXESTA FE in Pulmonary Arterial Hypertension. Press Release.

[3] ClinicalTrials.gov. (n.d.). Efficacy and Safety Study of NEXESTA FE in Patients With Pulmonary Arterial Hypertension (PAH) Associated With TPK-14 Mutation (NCT05129876). Retrieved from https://clinicaltrials.gov/ct2/show/NCT05129876

[4] U.S. Food and Drug Administration. (2024). Orphan Drug Designations. (Internal database record).

[5] Global PAH Patient Registry Consortium. (2022). Epidemiology of Pulmonary Arterial Hypertension Subtypes. Journal of Rare Diseases, 18(1), 45-59.

[6] BioGen Innovations. (2024). Investor Relations: NEXESTA FE Market Opportunity. Corporate Presentation.